Oneness Biotech Co., Ltd. (TPEX:4743)
Taiwan · Delayed Price · Currency is TWD 50.20
+4.55 (9.97%)
Nov 13, 2026, 1:21 PM CST
Oneness Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 139.97 | 129.12 | 117.93 | 86.78 | 1,066 | 65.77 | |
Revenue Growth | 19.30% | 9.50% | 35.89% | -91.86% | 1520.25% | 58.07% |
Cost of Revenue | 94.16 | 89.25 | 54.89 | 54.22 | 221.16 | 20.72 |
Gross Profit | 45.81 | 39.88 | 63.03 | 32.56 | 844.39 | 45.04 |
Selling, General & Admin | 253.81 | 233.09 | 223.55 | 176.64 | 166.83 | 117.22 |
Research & Development | 616.8 | 605.87 | 924.9 | 952.55 | 919.02 | 805.96 |
Other Operating Expenses | - | 3.93 | 0.63 | - | - | - |
Operating Expenses | 870.61 | 842.88 | 1,149 | 1,129 | 1,086 | 923.18 |
Operating Income | -824.81 | -803.01 | -1,086 | -1,097 | -241.45 | -878.14 |
Interest Expense | -8.02 | -8.9 | -9.61 | -5.61 | -4.6 | -4.9 |
Interest & Investment Income | 203.14 | 232.67 | 291.83 | 289.39 | 57.51 | 34.75 |
Earnings From Equity Investments | 213.58 | -253.9 | -428.9 | -498.78 | 90.02 | 280.31 |
Currency Exchange Gain (Loss) | -243.08 | -243.08 | 357.53 | -12.97 | 544.67 | -151.29 |
Other Non Operating Income (Expenses) | 442.52 | 4.77 | 6.58 | 7.08 | 8.68 | 12.01 |
EBT Excluding Unusual Items | -216.67 | -1,071 | -868.61 | -1,318 | 454.83 | -707.26 |
Gain (Loss) on Sale of Investments | -2.67 | -2.67 | 0.11 | -0.03 | -3.2 | 0.97 |
Gain (Loss) on Sale of Assets | 18.65 | 18.65 | -0.03 | 0.26 | - | - |
Asset Writedown | - | - | -279.7 | - | - | 6.19 |
Other Unusual Items | -0.59 | -0.59 | -1.51 | - | - | 304.13 |
Pretax Income | -201.28 | -1,056 | -1,150 | -1,317 | 451.63 | -395.96 |
Income Tax Expense | 14.61 | 3.47 | 3.29 | 5.29 | 99.73 | 16.86 |
Earnings From Continuing Operations | -215.88 | -1,060 | -1,153 | -1,323 | 351.9 | -412.82 |
Minority Interest in Earnings | -0.53 | 14.75 | -12.13 | 9.7 | 8.08 | 9.52 |
Net Income | -216.42 | -1,045 | -1,165 | -1,313 | 359.98 | -403.3 |
Net Income to Common | -216.42 | -1,045 | -1,165 | -1,313 | 359.98 | -403.3 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 479 | 479 | 478 | 474 | 465 | 455 |
Shares Outstanding (Diluted) | 479 | 479 | 478 | 474 | 472 | 455 |
Shares Change | -0.10% | 0.25% | 0.97% | 0.40% | 3.58% | 6.82% |
EPS (Basic) | -0.45 | -2.18 | -2.44 | -2.77 | 0.77 | -0.89 |
EPS (Diluted) | -0.45 | -2.18 | -2.44 | -2.77 | 0.76 | -0.89 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -238.22 | -482.21 | -395.28 | -512.23 | -968.35 | -384.24 |
Free Cash Flow Per Share | -0.50 | -1.01 | -0.83 | -1.08 | -2.05 | -0.84 |
Dividend Per Share | - | - | - | - | 0.084 | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 32.73% | 30.88% | 53.45% | 37.52% | 79.25% | 68.49% |
Operating Margin | -589.28% | -621.89% | -920.96% | -1263.64% | -22.66% | -1335.27% |
Profit Margin | -154.62% | -809.13% | -988.03% | -1512.82% | 33.78% | -613.25% |
Free Cash Flow Margin | -170.19% | -373.45% | -335.20% | -590.25% | -90.88% | -584.26% |
EBITDA | -550.47 | -516.5 | -681.01 | -674.23 | 231.23 | -712.66 |
EBITDA Margin | - | - | - | - | 21.70% | - |
D&A For EBITDA | 274.34 | 286.5 | 405.04 | 422.4 | 472.68 | 165.48 |
EBIT | -824.81 | -803.01 | -1,086 | -1,097 | -241.45 | -878.14 |
EBIT Margin | - | - | - | - | -22.66% | - |
Effective Tax Rate | - | - | - | - | 22.08% | - |